AC Immune SA announced positive preliminary Phase 1 data for ACI-19764, an orally administered small molecule inhibitor of the NLRP3 inflammasome. The drug demonstrated safety and tolerability in healthy volunteers across single and multiple ascending dose cohorts up to 20mg per day, with no serious adverse events. Key findings included confirmed cerebrospinal fluid penetration, a serum half-life exceeding 30 hours, and dose-dependent inhibition of IL-1beta release at daily doses of 10mg or less. The company has initiated dosing in a cardiovascular risk cohort to evaluate anti-inflammatory activity via hsCRP reduction, with initial results expected by year-end. Full Phase 1/1b trial results are anticipated in the first half of 2027. AC Immune SA is a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases.

On August 11, 2026, AC Immune SA announced it received Fast Track designation and Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration for its anti-alpha-synuclein active immunotherapy candidate, ACI-7104, intended to treat early-stage Parkinson’s disease. The company also disclosed a $4 million research grant from the Vijay and Marie Goradia Charitable Foundation to support the extension of Part 1 of the VacSYn Phase 2 trial for an additional two years. Interim results at 76 weeks demonstrated safety, tolerability, and immunogenicity with a 100% responder rate, while final week-100 results are expected in the second half of 2026. AC Immune SA is a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases.

AC Immune SA reported first-half 2026 financial results showing total revenue of CHF 16.2 million, driven by an CHF 11.0 million upfront payment and milestone from a Lilly agreement amendment and CHF 5.2 million in Takeda contract revenues. The company incurred a net loss of CHF 12.9 million, a significant improvement from the CHF 40.2 million loss in the prior year period, aided by reduced R&D expenses of CHF 22.2 million following a September 2025 reorganization. Liquidity stood at CHF 75.4 million as of June 30, 2026, providing funding through Q4 2027. The filing also announced that Dr. Andrea Pfeifer retired as CEO and Martin Zügel was appointed interim CEO. AC Immune is a clinical-stage biopharmaceutical company developing active immunotherapies and small molecules for neurodegenerative diseases.

On June 30, 2026, AC Immune SA announced 12-month data from the Phase 1b/2 ABATE Trial evaluating ACI-24 for the treatment of Prodromal Alzheimer’s Disease. The company operates in the biotechnology industry and develops immunotherapies for neurodegenerative diseases.